{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["MD simulation", "PD-1/PD-L1", "antibody design", "inhibitory mechanism", "monoclonal antibody"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29986511", "DateCompleted": {"Year": "2018", "Month": "10", "Day": "24"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "07", "Day": "07"}], "Language": ["eng"], "ELocationID": ["1984", "10.3390/ijms19071984"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "19", "Issue": "7", "PubDate": {"Year": "2018", "Month": "Jul", "Day": "07"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.", "Abstract": {"AbstractText": ["The anti-PD-L1 monoclonal antibody (mAb) targeting PD-1/PD-L1 immune checkpoint has achieved outstanding results in clinical application and has become one of the most popular anti-cancer drugs. The mechanism of molecular recognition and inhibition of PD-L1 mAbs is not yet clear, which hinders the subsequent antibody design and modification. In this work, the trajectories of PD-1/PD-L1 and nanobody/PD-L1 complexes were obtained via comparative molecular dynamics simulations. Then, a series of physicochemical parameters including hydrogen bond, dihedral angle distribution, p<i>K</i>a value and binding free energy, and so forth, were all comparatively analyzed to investigate the recognition difference between PD-L1 and PD-1 and nanobody. Both <sub>L</sub>R113 (the amino acid residues in PD-L1 are represented by the lower left sign of L) and <sub>L</sub>R125 residues of PD-L1 undergo significant conformational change after association with mAbs, which dominates a strong electrostatic interaction. Solvation effect analysis revealed that solvent-water enhanced molecular recognition between PD-L1 and nanobody. By combining the analyses of the time-dependent root mean squared fluctuation (RMSF), free energy landscape, clustering and energy decomposition, the potential inhibition mechanism was proposed that the nanobody competitively and specifically bound to the \u03b2-sheet groups of PD-L1, reduced the PD-L1\u2019s flexibility and finally blocked the formation of PD-1/PD-L1 complex. Based on the simulation results, site-directed mutagenesis of <sub>N</sub>D99 (the amino acid residues in Nano are displayed by the lower left sign of N) and <sub>N</sub>Q116 in the nanobody may be beneficial for improving antibody activity. This work offers some structural guidance for the design and modification of anticancer mAbs based on the structure of the PD-1/PD-L1 complex."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. sunbsxw123@163.com."}], "LastName": "Sun", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. yan_xiao163@163.com."}], "LastName": "Yan", "ForeName": "Xiao", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. zhuowei1989@163.com."}], "LastName": "Zhuo", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. gujinke@tsinghua.edu.cn."}], "LastName": "Gu", "ForeName": "Jinke", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. zuoke2015@outlook.com."}], "LastName": "Zuo", "ForeName": "Ke", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. liuwei@cdu.edu.cn."}], "LastName": "Liu", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. lianglicdu@163.com."}], "LastName": "Liang", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. Ganfcd@outlook.com."}], "LastName": "Gan", "ForeName": "Ya", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. hegang@cdu.edu.cn."}], "LastName": "He", "ForeName": "Gang", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Mathematics and Informatics, South China Agricultural University, Guangzhou 510642, China. wanhua@scau.edu.cn."}], "LastName": "Wan", "ForeName": "Hua", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. gxjmeprd@163.com."}], "LastName": "Gou", "ForeName": "Xiaojun", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of tumor targeted and immune therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. shihubing77@sina.com."}], "LastName": "Shi", "ForeName": "Hubing", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy and Biological Engineering, Sichuan Industrial Institute of Antibiotics, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, Chengdu 610106, China. hjpcdu@163.com."}], "LastName": "Hu", "ForeName": "Jianping", "Initials": "J"}], "PublicationTypeList": ["Comparative Study", "Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "B7-H1 Antigen"}, {"RegistryNumber": "0", "NameOfSubstance": "CD274 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "PDCD1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Programmed Cell Death 1 Receptor"}, {"RegistryNumber": "0", "NameOfSubstance": "Single-Domain Antibodies"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "genetics", "metabolism"], "DescriptorName": "B7-H1 Antigen"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Hydrogen Bonding"}, {"QualifierName": [], "DescriptorName": "Models, Molecular"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Mutagenesis, Site-Directed"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Programmed Cell Death 1 Receptor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Protein Binding"}, {"QualifierName": [], "DescriptorName": "Protein Structure, Secondary"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Single-Domain Antibodies"}], "CoiStatement": "The author declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Center M.M. Global cancer statistics. CA-Cancer J. Clin. 2015;65:69\u201390.", "ArticleIdList": ["21296855"]}, {"Citation": "Stewart B., Wild C. World Cancer Report 2014. International Agency for Research on Cancer; Lyon, France: 2014."}, {"Citation": "Eilard M.S., Lundgren L., Cahlin C., Strandell A., Svanberg T., Sandstr\u00f6m P. Surgical treatment for gallbladder cancer\u2014A systematic literature review. Scand. J. Gastroenterol. 2017;52:505\u2013514. doi: 10.1080/00365521.2017.1284895.", "ArticleIdList": ["10.1080/00365521.2017.1284895", "28270039"]}, {"Citation": "Feain I.J., Court L., Palta J.R., Beddar S., Keall P. Innovations in radiotherapy technology. J. Clin. Oncol. 2017;29:120\u2013128. doi: 10.1016/j.clon.2016.10.009.", "ArticleIdList": ["10.1016/j.clon.2016.10.009", "27913106"]}, {"Citation": "Rajasekaran T., Ng Q.S., Tan D.S., Lim W.T., Ang M.K., Toh C.K. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2017;388:328\u2013333. doi: 10.1016/j.canlet.2016.12.013.", "ArticleIdList": ["10.1016/j.canlet.2016.12.013", "28003122"]}, {"Citation": "Chen D.S., Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1\u201310. doi: 10.1016/j.immuni.2013.07.012.", "ArticleIdList": ["10.1016/j.immuni.2013.07.012", "23890059"]}, {"Citation": "Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432\u20131433. doi: 10.1126/science.342.6165.1432.", "ArticleIdList": ["10.1126/science.342.6165.1432", "24357284"]}, {"Citation": "Phan T.G., Long G.V., Scolyer R.A. Multiple checkpoints on the long road towards cancer immunotherapy. Immunol. Cell Biol. 2015;93:323\u2013325. doi: 10.1038/icb.2015.12.", "ArticleIdList": ["10.1038/icb.2015.12", "25686808"]}, {"Citation": "Antonia S.J., Larkin J., Ascierto P.A. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clin. Cancer Res. 2014;20:6258\u20136268. doi: 10.1158/1078-0432.CCR-14-1457.", "ArticleIdList": ["10.1158/1078-0432.CCR-14-1457", "25341541"]}, {"Citation": "Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u2013461. doi: 10.1016/j.ccell.2015.03.001.", "ArticleIdList": ["10.1016/j.ccell.2015.03.001", "PMC4400238", "25858804"]}, {"Citation": "Hao G., Wesolowski J.S., Jiang X., Lauder S., Sood V.D. Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches. J. Mol. Recognit. 2015;28:269\u2013276. doi: 10.1002/jmr.2418.", "ArticleIdList": ["10.1002/jmr.2418", "25664688"]}, {"Citation": "Zak K.M., Kitel R., Przetocka S., Golik P., Guzik K., Musielak B. Structure of the Complex of Human Programmed Death 1, PD-1 and Its Ligand PD-L1. Structure. 2015;23:2341\u20132348. doi: 10.1016/j.str.2015.09.010.", "ArticleIdList": ["10.1016/j.str.2015.09.010", "PMC4752817", "26602187"]}, {"Citation": "Riella L.V., Paterson A.M., Sharpe A.H., Chandraker A. Role of the PD-1 Pathway in the Immune Response. Am. J. Transplant. 2012;12:2575\u20132587. doi: 10.1111/j.1600-6143.2012.04224.x.", "ArticleIdList": ["10.1111/j.1600-6143.2012.04224.x", "PMC3784243", "22900886"]}, {"Citation": "Hawkes E.A., Grigg A., Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16:234\u2013245. doi: 10.1016/S1470-2045(15)70103-8.", "ArticleIdList": ["10.1016/S1470-2045(15)70103-8", "25943068"]}, {"Citation": "Wherry E.J. T cell exhaustion. Nat. Immunol. 2011;12:492\u2013499. doi: 10.1038/ni.2035.", "ArticleIdList": ["10.1038/ni.2035", "21739672"]}, {"Citation": "Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P. Safety and Activity of Anti\u2013PD-L1 Antibody in Patients with Advanced Cancer. New. Engl. J. Med. 2012;366:2455\u20132465. doi: 10.1056/NEJMoa1200694.", "ArticleIdList": ["10.1056/NEJMoa1200694", "PMC3563263", "22658128"]}, {"Citation": "Zhan M.M., Hu X.Q., Liu X.X., Ruan B.F., Xu J., Liao C. From monoclonal antibodies to small molecules: The development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov. Today. 2016;21:1027\u20131036. doi: 10.1016/j.drudis.2016.04.011.", "ArticleIdList": ["10.1016/j.drudis.2016.04.011", "27094104"]}, {"Citation": "Na Z., Yeo SP., Bharath SR., Bowler M.W., Bal\u0131k\u00e7\u0131 E., Wang C.I. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2016;27:147\u2013150. doi: 10.1038/cr.2016.77.", "ArticleIdList": ["10.1038/cr.2016.77", "PMC5223238", "27325296"]}, {"Citation": "Lee J.Y., Lee H.T., Shin W., Chae J., Choi J., Kim S.H. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Commun. 2016;7:13354. doi: 10.1038/ncomms13354.", "ArticleIdList": ["10.1038/ncomms13354", "PMC5095608", "27796306"]}, {"Citation": "Ibrahim R., Stewart R., Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin. Oncol. 2015;42:474\u2013483. doi: 10.1053/j.seminoncol.2015.02.007.", "ArticleIdList": ["10.1053/j.seminoncol.2015.02.007", "25965366"]}, {"Citation": "Zak K.M., Grudnik P., Magiera K., D\u00f6mling A., Dubin G., Holak T.A. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure. 2017;25:1163\u20131174. doi: 10.1016/j.str.2017.06.011.", "ArticleIdList": ["10.1016/j.str.2017.06.011", "28768162"]}, {"Citation": "Ahmed M., Barakat K.H. The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. Biochem.-US. 2017;56:428\u20135439. doi: 10.1021/acs.biochem.7b00655.", "ArticleIdList": ["10.1021/acs.biochem.7b00655", "28898057"]}, {"Citation": "Liu W., Liu G. Mapping Paratope and Epitope Residues of Antibody Pembrolizumab via Molecular Dynamics Simulation; Proceedings of the International Symposium on Bioinformatics Research and Applications; Honolulu, HI, USA. 29 May\u20132 June 2017; pp. 120\u2013127."}, {"Citation": "Zhang X., Schwartz J.C., Guo X., Bhatia S., Cao E., Lorenz M. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20:337\u2013347. doi: 10.1016/S1074-7613(04)00051-2.", "ArticleIdList": ["10.1016/S1074-7613(04)00051-2", "15030777"]}, {"Citation": "Cheng X., Veverka V., Radhakrishnan A., Waters L.C., Muskett F.W., Morgan S.H. Structure and Interactions of the Human Programmed Cell Death 1 Receptor. J. Biol. Chem. 2013;288:11771\u201311785. doi: 10.1074/jbc.M112.448126.", "ArticleIdList": ["10.1074/jbc.M112.448126", "PMC3636866", "23417675"]}, {"Citation": "Horita S., Nomura Y., Sato Y., Shimamura T., Iwata S., Nomura N. High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci. Rep.-UK. 2016;6:35297. doi: 10.1038/srep35297.", "ArticleIdList": ["10.1038/srep35297", "PMC5062252", "27734966"]}, {"Citation": "Tan S., Zhang H., Chai Y., Song H., Tong Z., Wang Q. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat. Commun. 2017;8:14369. doi: 10.1038/ncomms14369.", "ArticleIdList": ["10.1038/ncomms14369", "PMC5303876", "28165004"]}, {"Citation": "Lin D.Y., Tanaka Y., Iwasaki M., Gittis A.G., Su H.P., Mikami B. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA. 2008;105:3011\u20133016. doi: 10.1073/pnas.0712278105.", "ArticleIdList": ["10.1073/pnas.0712278105", "PMC2268576", "18287011"]}, {"Citation": "Chen Y., Liu P., Gao F., Cheng H., Qi J., Gao G.F. A dimeric structure of PD-L1: Functional units or evolutionary relics? Protein Cell. 2010;1:153\u2013160. doi: 10.1007/s13238-010-0022-1.", "ArticleIdList": ["10.1007/s13238-010-0022-1", "PMC4875164", "21203985"]}, {"Citation": "Fei Z., Wei H., Wang X., Bai Y., Wang P., Wu J. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004\u201317015.", "ArticleIdList": ["PMC5341541", "28280600"]}, {"Citation": "Liu K., Tan S., Chai Y., Chen D., Song H., Zhang C.W. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2016;27:151\u2013153. doi: 10.1038/cr.2016.102.", "ArticleIdList": ["10.1038/cr.2016.102", "PMC5223223", "27573173"]}, {"Citation": "Lee H.T., Lee J.Y., Lim H., Sang H.L., Yu J.M., Pyo H.J. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep-UK. 2017;7:5532\u20135544. doi: 10.1038/s41598-017-06002-8.", "ArticleIdList": ["10.1038/s41598-017-06002-8", "PMC5514103", "28717238"]}, {"Citation": "Pascolutti R., Sun X., Kao J., Maute R., Ring A.M., Bowman G.R. Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure. 2016;24:1719\u20131728. doi: 10.1016/j.str.2016.06.026.", "ArticleIdList": ["10.1016/j.str.2016.06.026", "PMC5052120", "27618663"]}, {"Citation": "Zak K.M., Grudnik P., Guzik K., Zieba B.J., Bogdan M., Alexander D. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) Oncotarget. 2016;7:30323\u201330335. doi: 10.18632/oncotarget.8730.", "ArticleIdList": ["10.18632/oncotarget.8730", "PMC5058683", "27083005"]}, {"Citation": "Guzik K., Zak K.M., Grudnik P., Magiera K., Musielak B., T\u00f6rner R. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J. Med. Chem. 2017;60:5857\u20135867. doi: 10.1021/acs.jmedchem.7b00293.", "ArticleIdList": ["10.1021/acs.jmedchem.7b00293", "28613862"]}, {"Citation": "Herbst R.S., Soria J.C., Kowanetz M. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u2013567. doi: 10.1038/nature14011.", "ArticleIdList": ["10.1038/nature14011", "PMC4836193", "25428504"]}, {"Citation": "Philips G.K., Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 2015;27:39\u201346. doi: 10.1093/intimm/dxu095.", "ArticleIdList": ["10.1093/intimm/dxu095", "25323844"]}, {"Citation": "Naidoo J., Page D.B., Li B.T., Connell L.C., Schindler K., Lacouture M.E. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015;26:2375\u20132391. doi: 10.1093/annonc/mdv383.", "ArticleIdList": ["10.1093/annonc/mdv383", "PMC6267867", "26371282"]}, {"Citation": "Gunturi A., Mcdermott D.F. Nivolumab for the treatment of cancer. Expert Opin. Investig. Drugs. 2015;24:253\u2013260. doi: 10.1517/13543784.2015.991819.", "ArticleIdList": ["10.1517/13543784.2015.991819", "25494679"]}, {"Citation": "Gangadhar T.C., Salama A.K. Clinical applications of PD-1-based therapy: A focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Oncotargets Ther. 2015;8:929\u2013937.", "ArticleIdList": ["PMC4410900", "25960664"]}, {"Citation": "Johnson D.B., Peng C., Sosman J.A. Nivolumab in melanoma: Latest evidence and clinical potential. Ther. Adv. Med. Oncol. 2015;7:97\u2013106. doi: 10.1177/1758834014567469.", "ArticleIdList": ["10.1177/1758834014567469", "PMC4346215", "25755682"]}, {"Citation": "Sharma P., Allison J.P. The future of immune checkpoint therapy. Science. 2015;348:56\u201361. doi: 10.1126/science.aaa8172.", "ArticleIdList": ["10.1126/science.aaa8172", "25838373"]}, {"Citation": "Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u2013562. doi: 10.1038/nature13904.", "ArticleIdList": ["10.1038/nature13904", "25428503"]}, {"Citation": "Alqudah D.A., Zihlif M.A., Taha M.O. Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors. Eur. J. Med. Chem. 2016;110:204\u2013223. doi: 10.1016/j.ejmech.2016.01.034.", "ArticleIdList": ["10.1016/j.ejmech.2016.01.034", "26840362"]}, {"Citation": "Tomii K., Hirokawa T., Motono C. Protein structure prediction using a variety of profile libraries and 3D verification. Proteins. 2005;61:114\u2013120. doi: 10.1002/prot.20727.", "ArticleIdList": ["10.1002/prot.20727", "16187352"]}, {"Citation": "Feig M., Karanicolas J., Brooks C.L. MMTSB Tool Set: Enhanced sampling and multiscale modeling methods for applications in structural biology. J. Mol. Graph. Model. 2004;22:377\u2013395. doi: 10.1016/j.jmgm.2003.12.005.", "ArticleIdList": ["10.1016/j.jmgm.2003.12.005", "15099834"]}, {"Citation": "Hu J., Hu Z., Zhang Y., Gou X., Mu Y., Wang L. Metal binding mediated conformational change of XPA protein: A potential cytotoxic mechanism of nickel in the nucleotide excision repair. J. Mol. Model. 2016;22:1\u201319. doi: 10.1007/s00894-016-3017-x.", "ArticleIdList": ["10.1007/s00894-016-3017-x", "PMC5327499", "27307058"]}, {"Citation": "Knapp B., Lederer N., Omasits U., Schreiner W. vmdICE: A plug-in for rapid evaluation of molecular dynamics simulations using VMD. J. Comput. Chem. 2010;31:2868\u20132873. doi: 10.1002/jcc.21581.", "ArticleIdList": ["10.1002/jcc.21581", "20928849"]}, {"Citation": "Kabsch W., Sander C. Dictionary of protein secondary structure. Biopolymers. 1983;22:2577\u20132637. doi: 10.1002/bip.360221211.", "ArticleIdList": ["10.1002/bip.360221211", "6667333"]}, {"Citation": "Dolinsky T.J., Nielsen J.E., Mccammon J.A., Baker N.A. PDB2PQR: An automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32:W665\u2013W667. doi: 10.1093/nar/gkh381.", "ArticleIdList": ["10.1093/nar/gkh381", "PMC441519", "15215472"]}, {"Citation": "Ahmed M., Barakat K. When theory meets experiment: The PD-1 challenge. J. Mol. Model. 2017;23:308\u2013313. doi: 10.1007/s00894-017-3482-x.", "ArticleIdList": ["10.1007/s00894-017-3482-x", "29019005"]}, {"Citation": "Basu S., Mukharjee D. Salt-bridge networks within globular and disordered proteins: Characterizing trends for designable interactions. J. Mol. Model. 2017;23:206\u2013230. doi: 10.1007/s00894-017-3376-y.", "ArticleIdList": ["10.1007/s00894-017-3376-y", "28626846"]}, {"Citation": "Zhao W.S., Sun M.Y., Sun L.F., Liu Y., Yang Y., Huang L.D. A Highly Conserved Salt Bridge Stabilizes the Kinked Conformation of \u03b22,3-Sheet Essential for Channel Function of P2X4 Receptors. J. Biol. Chem. 2016;291:7990\u20138005. doi: 10.1074/jbc.M115.711127.", "ArticleIdList": ["10.1074/jbc.M115.711127", "PMC4825005", "26865631"]}, {"Citation": "Kumar S., Nussinov R. Salt bridge stability in monomeric proteins. J. Mol. Biol. 1999;293:1241\u20131255. doi: 10.1006/jmbi.1999.3218.", "ArticleIdList": ["10.1006/jmbi.1999.3218", "10547298"]}, {"Citation": "Hu J.P., Gong X.Q., Su J.G., Chen W.Z., Wang C.X. Study on the molecular mechanism of inhibiting HIV-1 integrase by EBR28 peptide via molecular modeling approach. Biophys. Chem. 2008;132:69\u201380. doi: 10.1016/j.bpc.2007.09.008.", "ArticleIdList": ["10.1016/j.bpc.2007.09.008", "18037557"]}, {"Citation": "Cummings C.G., Hamilton A.D. Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr. Opin. Chem. Biol. 2010;14:341\u2013346. doi: 10.1016/j.cbpa.2010.04.001.", "ArticleIdList": ["10.1016/j.cbpa.2010.04.001", "20430687"]}, {"Citation": "Case D.A., Darden T.A., Cheatham T.E., III, Simmerling C.L., Wang J., Duke R.E., Luo R., Walker R.C., Zhang W., Merz K.M., et al. AMBER 12. University of California; San Francisco, CA, USA: 2012."}, {"Citation": "Wang J., Cieplak P., Komllman P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules. J. Comput. Chem. 2000;21:1049\u20131074. doi: 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F.", "ArticleIdList": ["10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F"]}, {"Citation": "Jorgense W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926\u2013935. doi: 10.1063/1.445869.", "ArticleIdList": ["10.1063/1.445869"]}, {"Citation": "Ryckaert J.P., Ciccotti G., Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Chem. Phys. 1977;23:327\u2013341. doi: 10.1016/0021-9991(77)90098-5.", "ArticleIdList": ["10.1016/0021-9991(77)90098-5"]}, {"Citation": "Hegger R., Altis A., Nguyen P.H., Stock G. How complex is the dynamics of Peptide folding? Phys. Rev. Lett. 2007;98:028102. doi: 10.1103/PhysRevLett.98.028102.", "ArticleIdList": ["10.1103/PhysRevLett.98.028102", "17358652"]}, {"Citation": "Talavera D., Robertson D.L., Lovell S.C. Characterization of Protein-Protein Interaction Interfaces from a Single Species. PLoS ONE. 2011;6:e21053. doi: 10.1371/journal.pone.0021053.", "ArticleIdList": ["10.1371/journal.pone.0021053", "PMC3124478", "21738603"]}, {"Citation": "Peri C., Morra G., Colombo G. Surface energetics and protein-protein interactions: Analysis and mechanistic implications. Sci. Rep. 2016;6:24035. doi: 10.1038/srep24035.", "ArticleIdList": ["10.1038/srep24035", "PMC4822145", "27050828"]}, {"Citation": "Kumari R., Kumar R., Lynn A. G_mmpbsa\u2014A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 2014;54:1951\u20131962. doi: 10.1021/ci500020m.", "ArticleIdList": ["10.1021/ci500020m", "24850022"]}, {"Citation": "Kottalam J., Case D.A. Langevin modes of macromolecules: Applications to crambin and DNA hexamers. Biopolymers. 1990;29:1409\u20131421. doi: 10.1002/bip.360291008.", "ArticleIdList": ["10.1002/bip.360291008", "2361153"]}, {"Citation": "Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc. Chem. Res. 2000;33:889\u2013897. doi: 10.1021/ar000033j.", "ArticleIdList": ["10.1021/ar000033j", "11123888"]}, {"Citation": "Catalysis E., Wang W., Donini O., Reyes C.M., Kollman P.A. Biomolecular simulations: Recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein and protein-nucleic acid noncovalent interactions. Annu. Rev. Biophys. Biomol. Struct. 2001;30:211\u2013243.", "ArticleIdList": ["11340059"]}, {"Citation": "Simonson T. Macromolecular electrostatics: Continuum models and their growing pains. Curr. Opin. Struc. Biol. 2001;11:243\u2013252. doi: 10.1016/S0959-440X(00)00197-4.", "ArticleIdList": ["10.1016/S0959-440X(00)00197-4", "11297935"]}, {"Citation": "Bashford D., Case D.A. Generalized born models of macromolecular solvation effects. Annu. Rev. Phys. Chem. 2000;51:129\u2013152. doi: 10.1146/annurev.physchem.51.1.129.", "ArticleIdList": ["10.1146/annurev.physchem.51.1.129", "11031278"]}, {"Citation": "Still W.C., Tempczyk A., Hawley R.C., Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990;112:6127\u20136129. doi: 10.1021/ja00172a038.", "ArticleIdList": ["10.1021/ja00172a038"]}, {"Citation": "Weiser J., Shenkin P.S., Still W.C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) J. Comput. Chem. 1999;20:217\u2013230. doi: 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A.", "ArticleIdList": ["10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A"]}]}], "History": [{"Year": "2018", "Month": "6", "Day": "1"}, {"Year": "2018", "Month": "7", "Day": "2"}, {"Year": "2018", "Month": "7", "Day": "4"}, {"Year": "2018", "Month": "7", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["29986511", "PMC6073277", "10.3390/ijms19071984", "ijms19071984"]}}]}